Farber, Beth Israel cancer hospital construction begins

Key Points:

• Dana-Farber is building a new 300-bed, 450,000-square-foot cancer hospital on the former Joslin Diabetes Center site, set to open in 2031, marking a major expansion of its inpatient care capabilities.
• The hospital symbolizes Dana-Farber’s new partnership with Beth Israel Lahey Health, moving away from its longtime collaboration with Mass General Brigham (MGB), with patient and clinical transitions occurring over several years.
• The new facility will connect directly to Beth Israel Deaconess Medical Center via a dedicated bridge and will focus on specialized cancer care, including 30 ICU beds and a 16-bed observation suite designed with patient comfort and infection control in mind.
• Dana-Farber plans to hire approximately 2,400 staff for the hospital, intensifying competition with MGB, which is simultaneously investing $400 million in its own cancer institute and facilities across multiple locations.
• Both health systems emphasize distinct approaches to cancer care: Dana-Farber focuses on a dedicated, tailored hospital experience, while MGB promotes integrated, holistic care across its network; patient choice remains a priority in treatment location.